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Maternal supplementation with long-chain PUFA, to improve infant neurological development, might cause additional increase of oxidative stress.
Pregnant women aged 18–41 years were randomised into one of four supplementation groups. From week 22 on, they received supplements
containing either modified fish oil (n 69), 5-methyl-tetrahydro-folate (n 65), both (n 64), or placebo (n 72). Plasma Trolox-equivalent antioxidative
capacity (TEAC), concentrations of a-tocopherol, retinol, b-carotene, free thiol groups, uric acid and thiobarbituric acid-reactive substances
(TBARS) were determined at weeks 20 and 30 and at delivery. The studied antioxidants showed no significant differences between the four
supplementation groups. At week 30 plasma TBARS levels were found to be significantly higher in the fish oil group (0·80 (SEM 0·04)mmol/l)
than in the folate (0·67 (SEM 0·03)mmol/l; P¼0·024) and control (0·69 (SEM 0·04)mmol/l; P¼0·01) groups. Concentrations of retinol and free
thiol groups decreased during pregnancy, whereas uric acid increased and b-carotene as well as TEAC showed only minor changes. Fish oil
supplementation during the second half of pregnancy appears not to decrease antioxidant status. The increased TBARS levels at week 30 may
indicate a period of increased oxidative stress in plasma at this time.
Pregnancy: DHA: Oxidative stress: Thiobarbituric acid-reactive substances
Oxidative stress occurs as a result of an increase in oxidant
generation, a decrease in antioxidant protection, or a failure to
repair oxidative damage. Damage to cells results from reactive
oxygen species-induced alteration of PUFA in membrane
lipids, proteins and DNA. During pregnancy, oxidative stress
increases, but there is also an increase of antioxidants and anti-
oxidative enzymes(1,2). Imbalances between oxidants and the
antioxidative system may be associated with the onset of
pre-eclampsia(3,4) and with an increased risk of miscarriage(1).
Furthermore, an inverse correlation between the maternal
oxidative stress biomarkers malondialdehyde (for lipid peroxi-
dation) and 8-hydroxydeoxyguanosine (for DNA peroxidation)
and neonatal birth weight has been demonstrated(5).
Increased availability of n-3 long-chain PUFA, for example,
DHA, during the perinatal period has been reported to improve
cognitive and visual development of the infant(6 – 8). The fetus
accumulates up to 50 mg DHA per d in brain and adipose
tissue during the last 3 months of gestation(9). Fish oil sup-
plementation in pregnancy was found to slightly prolong mean
duration of gestation time and to markedly lower the risk for
early preterm delivery(10,11). However, long-chain PUFA are
susceptible to peroxidation(12) and additional oxidative stress
might be caused by a high dietary intake of n-3 fatty acids
without adequate antioxidative protection(13).
In women of childbearing age adequate folate supply
reduces the incidence of neural tube defects in infants and
in the general population. Folate supplementation can reduce
plasma concentrations of homocysteine(14). During pregnancy
this might improve placental vascularisation and hence
maternal–fetal substrate transfer. In line with this hypothesis
Böhles et al. showed a negative correlation between maternal
plasma homocysteine and DHA-percentage in the erythrocyte
membrane phospholipids of their newborns(15). Thus a
combined supplementation with folate and n-3 long-chain
PUFA seems reasonable. As several reactions of homocysteine
metabolism (for example, formation of homocysteine)
promote the formation of reactive oxygen species, folate sup-
plementation might beneficially influence redox markers(16).
The aim of the present study was to compare oxidative
stress and antioxidant levels in pregnant women with and
without an n-3 long-chain PUFA supplementation, considering
a potentially confounding influence of folate supplementation.
Since redox status cannot be adequately assessed from a
single analytical parameter, we analysed a set of biomarkers
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in the plasma of pregnant women participating in a random-
ised clinical trial on the effect of fish oil supplemen-
tation during the second half of pregnancy on pregnancy
outcome(17). Vitamin E is the major lipid-soluble, peroxidation
chain-breaking antioxidant(18). b-Carotene is an effective
scavenger of peroxyl radicals(19) and it is a precursor of
retinol, which is of essential importance for growth and deve-
lopment of cells and tissues. Uric acid is a powerful scavenger
of singlet oxygen and other radicals(20). Thiol groups, mainly
from glutathione, are susceptible to oxidative changes and
play an important role in antioxidative reactions(21). Because
there are more antioxidants and interactions in the aqueous
phase of plasma, we measured Trolox-equivalent antioxidant
capacity (TEAC) in plasma as an integrative parameter.
In addition, the plasma concentration of thiobarbituric acid-




The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki and all procedures
involving human subjects were approved by the local
Ethical Committees of the participating centres. From Novem-
ber 2001 to March 2003, pregnant women were recruited in
Granada (Spain), Pécs (Hungary) and Munich (Germany).
Women attending antenatal care clinics for ultrasound
examinations between week 12 and week 20 of gestation
were approached by study personnel, informed about the
aims and nature of the study and invited to participate. Subject
information includes an oral explanation by the physician
and a written informed consent which was given to the
subject. The criteria for inclusion were: age at study entry of
18–41 years, uncomplicated singleton pregnancy and weight
at study entry of 50–95 kg. Women taking folate supplements
after week 16 of gestation or fish oil supplements since they
became pregnant were excluded from the study. Furthermore,
for this analysis all women who smoked during pregnancy
were excluded because smoking may enhance oxidative
stress. Details of the study protocol and execution have been
previously reported(17).
Participants who agreed to participate were randomised
without stratification into one of four dietary supplementation
groups separately at each centre. To ensure that the different
supplementation groups are nearly equally represented in
each centre, randomisation was performed in blocks of
twenty numbers. For this purpose twenty envelopes containing
cards with one of the four numbers according to the
supplementation groups were prepared and put into a closed
box. By drawing envelopes, supplementation group numbers
were assigned to the subject identity number. This procedure
was performed identically for each study centre. After
allocation to the dietary group, women were provided
correspondingly with ninety sachets of 15 g, of which they
had to consume one per d. At the second investigation date
in week 30 ^ 1 (w30) of gestation a further batch of ninety
sachets was provided for the rest of pregnancy.
Thus, from week 22 of gestation onwards participants
received milk-based supplements containing either modified
fish oil providing 500 mg DHA and 150 mg EPA per d
(fish oil group), or 400mg 5-methyl-tetrahydro-folate
(MTHF) per d (folate group), both in combination (fish oil þ
MTHF; fish oil þ folate group) or placebo (control group).
All supplements provided the estimated additional require-
ments for minerals and vitamins during the second half of
pregnancy (Table 1).
Non-fasting maternal venous blood samples for the
laboratory analyses were collected at week 20 ^ 1 (w20) of
gestation, before supplementation started, at w30 and at the
time of delivery using EDTA as anticoagulant. The plasma
samples were stored at 2808C until assayed. At the same
time points a well-trained physician performed standardised
interviews with the woman to assess data about socio-
economic status, obstetrical history, intercurrent diseases and
maternal smoking habits. Additionally, maternal height,
weight and blood pressure were measured. At w20 and w30
participating women completed a FFQ to assess the DHA
and folate intake with their habitual diet. Details of the nutri-
tional evaluation have previously been reported(22).
Analytical procedures
TBARS, TEAC, free thiol-groups, total protein and uric acid
concentrations from all samples of each woman were analysed
during one and the same day.
TBARS concentrations were determined by reaction
with 2-thiobarbituric acid, based on the method of Knight
et al. (23). Ortho-phosphoric acid (500ml; 0·44 M), 100ml
plasma and 200ml 2-thiobarbituric acid solution (60 mg
per 10 ml water) were pipetted into reaction vials. The
mixture was heated in a water-bath for 1 h to 1008C. After
cooling, a 100ml sample was added to a 100ml methanol–
NaOH mixture (0·45 ml 1 M-NaOH per 4·55 ml methanol).
Table 1. Nutrition, mineral and vitamin content of the supplements
according to manufacturer’s analysis (nutrient supply per sachet of 15 g)
Group. . . Fish oil Folate Fish oil þ folate Control
DHA (mg) 500 – 500 –
EPA (mg) 150 150
5-MTHF (mg) – 400 400 –
Energy
kJ 297 293 297 293
kcal 71 70 71 70
Protein (g) 2·5 2·9 2·5 2·9
Fat (g) 3·1 2·9 3·1 2·9
Carbohydrates (g) 8·2 8·0 8·2 8·0
Vitamin A (mg) 330 330 330 330
Vitamin D (mg) 1·5 1·5 1·5 1·5
Vitamin E (mg) 3 3 3 3
Thiamin (mg) 0·36 0·36 0·36 0·36
Riboflavin (mg) 1·5 1·5 1·5 1·5
Niacin (mg) 4·5 4·5 4·5 4·5
Vitamin B6 (mg) 1·9 1·9 1·9 1·9
Vitamin B12 (mg) 3·5 3·5 3·5 3·5
Vitamin C (mg) 270 270 270 270
Ca (mg) 300 300 300 300
P (mg) 240 240 240 240
Mg (mg) 93 93 93 93
Zn (mg) 3 3 3 3
I (mg) 66 66 66 66
5-MTHF, 5-methyl-tetrahydro-folate.
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After centrifugation a 50ml portion of the supernatant fraction
was used for HPLC with fluorescence detection (excitation,
550 nm; emission, 532 nm) for the measurement of TBARS(23).
External calibration with 1,1,3,3-tetraethoxypropane was used
to quantify TBARS in the plasma samples. Intra- and inter-
assay CV were 2·6 and 8·8 %, respectively.
Plasma a-tocopherol, retinol and b-carotene concentrations
were analysed at the Department of Paediatrics, University
of Frankfurt am Main (Germany) by an established HPLC
method with UV detection after extraction of lipids into
hexane(24). An external standard was applied for quantification.
Plasma a-tocopherol is given as concentration and in relation
to plasma lipids (a-tocopherol:cholesterol þ TAG ratio).
Free thiol-groups were determined using Ellman’s reagent
(5,50-dithio-bis 2-nitrobenzoic acid)(25). Micro-plate wells
were filled with 165ml water, 60ml phosphate-saline buffer
(0·1 M), 15ml plasma or standard and 60ml Ellman’s reagent
(10 mM in 0·15 M-NaCl and 0·1 M-Na3PO4). Blanks were
measured with each plasma sample, containing distilled
water instead of Ellman’s reagent, and one blank containing
pure water instead of plasma. The reaction was allowed to pro-
ceed during incubation at room temperature for at least 15 min
on a shaker plate, before absorption was measured at 405 nm
(photometer anthos ht III; Labtec Instruments, Wals, Austria).
A five-point calibration curve was prepared daily using fresh
cysteine solution. Intra- and inter-assay CV averaged 6·6
and 8·9 %, respectively.
The measurement of TEAC is based on the inhibition
of the formation of 2,20-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) (ABTSþ) radical cations by antioxidants(26).
PBS buffer (506ml; 5 mM; pH 7·4), 36ml myoglobine (70mM),
300ml 2,20-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)
(500mM) and 8·4ml plasma were combined. The mixture
was incubated for 3 min at 308C. The reaction was started
by the addition of 150ml H2O2 (450mM), which was
prepared fresh every day, and after 3 min absorbance at
734 nm was read. Trolox (6-hydroxy-2,5,7,8-tetramethylchro-
man-2-carboxylic acid diluted in 2·5 mM-PBS) was used for
calibration. The intra- and inter-assay CV averaged 1·1 and
4·7 %, respectively.
Cholesterol, TAG, total protein and uric acid were
analysed with an automatic Hitachi analysis system (Fa.
Boehringer, Mannheim, Germany), using enzymic assays
for cholesterol, TAG, uric acid and a colour test for total
protein, respectively.
Statistical analysis
Data were analysed with SPSS for Windows 12.0 (SPSS Inc.,
Chicago, IL, USA). Normal distribution was examined using
the Kolmogorow–Smirnov test (with Lilliefors correction).
One-way ANOVA with post hoc Bonferroni correction was
used to evaluate differences between supplementation groups
for normally distributed data. In the case of non-normal
distribution the Mann–Whitney U test was applied. Statistical
significance was assumed at P,0·05. Differences over time
were evaluated using a general linear model. Correlations
between parameters were estimated by computing Pearson’s
correlation coefficient in the case of normally distributed
values and the Spearman r correlation coefficient in the case
of other distributions, respectively.
Results
Study participants
From the 311 women enrolled into the study, forty-one women
were excluded from the analyses because they did not
complete the study. Reasons for dropping out were non-
compliance (n 2), relocation (n 1), aversion to or bad taste
of the supplement (n 9), and the loss of contact (n 2). For
the remaining cases, a special reason for drop out could not
be identified. From 270 study participants who completed
the study(17), samples were available for sixty-five women
recruited in Munich, 113 in Granada and fifty-four in Pècs,
respectively. Allocation of these women to the different inter-
vention groups was: fish oil group (n 69), folate group (n 65),
control group (n 72) and fish oil þ folate group (n 64). Age
and BMI were not significantly different between the four
supplementation groups at study entry (Table 2). The four
supplementation groups differed at none of the time points
in BMI and weight gain during pregnancy. The whole
study population showed an average weight gain of 5·8 (SEM
3·8) kg from w20 to w30 and 4·2 (SEM 3·5) kg from w30
until the end of pregnancy. Weight development was not
different between the groups.
Effects of fish oil and folate supplementation on maternal
plasma
Plasma cholesterol levels were significantly different over
time of pregnancy in the whole study population (w20, 5·72
Table 2. Characteristics of the participants in the four supplementation groups*
(Median values and interquartile ranges (IQR))
Group. . . Fish oil Folate Control Fish oil þ folate
Total study
population
Median IQR Median IQR Median IQR Median IQR Median IQR P
Age at study entry
(years)
31·2 27·4–34·0 31·9 26·1–35·2 31·0 28·4–34·8 31·9 28·0–35·2 31·3 27·6–34·8 0·62
BMI (kg/m2)
w20 25·2 22·8–28·2 24·3 22·2–27·3 24·2 23·0–26·6 24·5 23·1–27·2 24·6 22·8–27·4 0·42
w30 27·7 25·0–31·6 26·2 24·2–28·3 26·4 25·0–29·1 26·2 24·6–29·1 26·5 24·7–29·5 0·37
Delivery 29·1 26·4–33·0 27·5 25·3–30·3 28·4 26·6–31·1 28·2 26·4–31·2 28·4 26·4–31·3 0·27
w20, Week 20 ^ 1 of gestation; w30, week 30 ^ 1 of gestation.
* Group-specific statistical differences were assessed by ANOVA (with Bonferroni correction) and the Kruskal–Wallis test.
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(SEM 0·06); w30, 6·64 (SEM 0·08); delivery, 6·24 (SEM
0·09) mmol/l; P,0·001). In all supplementation groups the
highest plasma mean cholesterol value was found at w30
and the lowest at baseline, before supplementation started
(Table 3). A significant difference (P¼0·003) at w30 was
found between women supplemented with fish oil (fish oil
and combined groups: 6·78 (SEM 0·10) mmol/l) and non-
supplemented women (folate and control groups: 6·18 (SEM
0·17) mmol/l). There were no other significant differences
between the supplementation groups. Plasma TAG values
increased significantly with advancing pregnancy (w20, 1·72
(SEM 0·04); w30, 2·26 (SEM 0·05); delivery, 2·30 (SEM
0·06) mmol/l; P,0·01) without significant group differences
at the different time points (P¼0·30; Table 3).
Supplementation did not affect plasma total protein levels
(general linear model: P¼0·723). But all supplementation
groups showed time-dependent changes. With exception of
the combined group (P¼0·04), total plasma protein levels
were similar at w20 and w30 and decreased towards delivery
in all groups (P,0·001; Table 3). Between all time points
we found significant correlations for plasma total protein
(w20–w30, r 0·54; w30–delivery, r 0·34; P,0·001).
Plasma TBARS concentrations at w20 showed no signifi-
cant differences between the supplementation groups. At
w30 we found a significant difference between the DHA
group and the folate group (P¼0·047; Fig. 1). In all four
groups, plasma TBARS increased significantly from w30
until the end of pregnancy. Subjects with n-3 long-chain
PUFA in their supplement, with or without folate, had
higher plasma TBARS concentrations at w30 (P¼0·042) and
at delivery than non-n-3 long-chain PUFA-supplemented
groups (P¼0·030; Fig. 2). Plasma TBARS level showed no
differences from w20 to w30 in groups with the fish oil
supplement, but decreased significantly without the fish oil
supplement (P¼0·001; Fig. 2). We found no significant
effect of the study supplement on the plasma TBARS levels
(general linear model: P¼0·305). Plasma TBARS correlations
between the different time points in the whole study group
(w20–w30, r 0·35, P,0·001; w30–delivery, r 0·21, P¼0·03)
and in women with fish oil supplementation (fish oil and com-
bined groups) were statistically significant (w20–w30, r 0·22,
P¼0·021; w30–delivery, r 0·28, P¼0·006). However, there
was only a significant correlation in the subjects not sup-


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1. Maternal thiobarbituric acid-reactive substances (TBARS) plasma
levels in the different supplementation groups over time: week 20 ^ 1 of
gestation (w20; A); week 30 ^ 1 of gestation (w30; ); delivery (B). Values
are medians, with interquartile ranges represented by vertical bars. * Median
value was significantly different from that at w20 (P,0·05). † Median value
was significantly different from that at w30 (P,0·05). ‡ Median value was
significantly different from that of the fish oil group at w30 (P,0·05).
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w20 and w30 (w20–w30, r 0·37, P,0·001; w30–delivery,
r 0·05; NS). Only at w30 were there significant negative
correlations between TBARS and the plasma a-tocopherol
concentration (r 20·21; P¼0·002) and the a-tocopherol:lipids
ratio (r 20·24; P,0·001).
The concentration of plasma a-tocopherol was related to
total lipids (cholesterol þ TAG) and rose between w20 and
w30 significantly in all four supplementation groups
(P,0·001). From w30 until the end of pregnancy the
plasma a-tocopherol concentrations showed no differences
in all groups (Table 4). Supplementation had no effect
on the plasma a-tocopherol:lipid ratio; during the whole
intervention time no differences were found between the sup-
plementation groups. Significant intra-individual correlations
of the a-tocopherol:lipid ratio in the study population were
found between w20 and w30 (r 0·27; P,0·001) as well as
w30 and delivery (r 0·27; P,0·001). Correlations between
these time points were also significant for a-tocopherol
concentrations (w20–w30, r 0·45, P,0·001; w30–delivery,
r 0·40, P,0·001).
Plasma TEAC was not affected by supplementation at any
time point (Table 4). There were no significant changes over
time and no differences between fish oil-supplemented and
non-fish oil-supplemented women (Fig. 2). Significant intra-
individual correlations of TEAC at all time points were
found in the total population (w20–w30, r 0·82, P,0·001;
w30–delivery, r 0·70, P,0·001). Plasma TEAC levels
correlated significantly with b-carotene levels at w20 (r 0·18;
P¼0·006) and w30 (r 0·14; P¼0·034). Other correlations were
obtained between TEAC and retinol (w20, r 0·32, P,0·001;
w30, r 0·28, P,0·001; delivery, r 0·21, P¼0·002), TEAC
and a-tocopherol (w30, r 0·29, P,0·001; delivery, r 0·45;
P,0·001) as well as between TEAC and total protein (w20,
r 0·17, P¼0·009; delivery, r 0·36; P,0·001). No correlations
were found between TEAC and uric acid and the free thiol
groups, respectively.
Maternal retinol levels decreased in the whole study
population with increasing duration of pregnancy (P,0·001;
w20, 2·74 (SEM 0·08)mmol/l; w30, 2·18 (SEM 0·07)mmol/l;
delivery, 1·99 (SEM 0·07)mmol/l). Significant changes between
w20 and w30 were found in all four groups (Table 4) and a
significant change between w30 and delivery was found in
the fish oil group (P¼0·008). Splitting women into subjects
with (fish oil and combined groups) and without fish
oil supplementation (folate þ control groups) resulted in
significant differences between w20 and w30 in both groups
(with fish oil: P¼0·002, w20, 2·70 (SEM 0·11)mmol/l; w30,
2·2 (SEM 0·10)mmol/l; without fish oil: P,0·001, w20,
2·72 (SEM 0·11)mmol/l; w30, 1·99 (SEM 0·09)mmol/l) and
between w30 and delivery only in fish oil-supplemented
women (P¼0·002; delivery, 1·86 (SEM 0·12)mmol/l). Between
supplementation groups we found no significant differences
at any of the time points. Intra-individual correlations of
the plasma retinol levels were significant between all
time points (w20–w30, r 0·40, P,0·001; w30–delivery,
r 0·23; P,0·001).
The plasma b-carotene levels showed different develop-
ments in women with and without fish oil supplementation.
Both the folate and control groups showed a significant
decrease between w20 and w30 (P¼0·014; P¼0·002), as
well as all subjects without fish oil supplementation taken
together (control and folate groups: w20, 0·52 (SEM
0·04)mmol/l; w30, 0·41 (SEM 0·04)mmol/l; P,0·001). In all
groups, the lowest plasma b-carotene concentration was
found at the end of pregnancy. There were no significant
differences between the four supplementation groups at any
of the time points. Comparing women with fish oil (fish oil
and combined groups) and those without fish oil supplemen-
tation (control and folate groups), we found a significant
difference at w30 (P¼0·03) and delivery (P¼0·04). In
both cases, women with fish oil supplementation had higher
b-carotene concentrations (with fish oil: w30, 0·51 (SEM
0·04)mmol/l; delivery, 0·42 (SEM 0·03)mmol/l; without fish
oil: w30, 0·42 (SEM 0·04)mmol/l; delivery, 0·38 (SEM 0·04)
mmol/l). Correlations between the time points were significant
(w20–w30, r 0·60; w30–delivery, r 0·75; P,0·001) in the
whole study population.
Plasma free thiol groups decreased until the end of
pregnancy, but no differences were found between the four
supplementation groups, as well as between fish oil-
supplemented (fish oil and combined groups) and non-fish
oil-supplemented (control and folate groups) subjects.
A significant decrease between w30 and delivery was found
in all four groups (Table 4). Correlations were significant
between all time points (w20–w30, r 0·49; w30–delivery,
r 0·45; each P,0·001). At all time points we found significant
correlations between the concentrations of total protein and
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Fig. 2. Plasma thiobarbituric acid-reactive substances (TBARS) (a) and
Trolox-equivalent antioxidant capacity (TEAC) (b) values in women with ( )
and without (A) fish oil in their supplementation over time: week 20 ^ 1 of
gestation (w20); week 30 ^ 1 of gestation (w30); delivery. Values are
medians, with interquartile ranges represented by vertical bars. * Median
value was significantly different from that of the women receiving the fish oil
supplementation at the same time point (P¼0·042). † Median value was
significantly different from that of the women receiving the fish oil supplemen-
tation at the same time point (P¼0·030). ‡ Median value was significantly
different from that of the women not receiving the fish oil supplementation at
w20 (P¼0·001).
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delivery, r 0·44, P,0·001). The ratio of thiol groups per total
protein did not differ between the supplementation groups.
In the whole study population, plasma uric acid level
showed a slight increase between w20 and w30 (510
(SEM 14) to 551 (SEM 8)mmol/l; P,0·001) and a stronger
increase towards the end of pregnancy (739 (SEM 13)mmol/l;
P,0·001). There was no significant effect of the supplemen-
tation on maternal uric acid level during intervention time
(general linear model: P¼0·60). Except the folate group
(P¼0·07), all groups showed a significant increase between
w20 and w30 (P#0·001). Between w30 and delivery, all
four groups showed a significant increase (P,0·001). Signifi-
cant correlations with P,0·001 were found between w20 and
w30 (r 0·65) as well as w30 and delivery (r 0·60) in the total
study population.
Dietary intake of DHA
The analysis of the FFQ showed no significantly different
DHA intake with habitual diet between the supplementation
groups at w20 and w30. DHA intake in the study population
was 30·1 mg per 1000 kJ (126 mg per 1000 kcal) at w20
and 29·4 mg per 1000 kJ (123 mg per 1000 kcal) at w30 on
average(22). We found no significant difference regarding
the dietary intakes of folate between the four supplementation
groups at w20 nor at w30. The study population showed a
folate intake of about 27·7mg/1000 kJ (116mg/1000 kcal) at
both time points with no significant difference between the
groups and change with time.
Discussion
The present study shows a significant increase of plasma
TBARS during the second half of pregnancy, independently
from supplement allocation. An increase of lipid peroxidation
was previously reported with progression of pregnancy, and
thus with increasing age of the placenta(27). While measures
of peroxidation are generally higher in pregnant women
than in non-pregnant controls, results on the evolution of
plasma markers of peroxidation during pregnancy are quite
variable(28). The significant increase of TBARS in our subjects
is in line with the reported increase of lipid hydroperoxides
between first and third trimester(29), while a significant
increase of plasma malondialdehyde concentration with the
course of pregnancy was not observed by Patrick et al. in
American women(30). A reason for these divergent results
might be that the TBARS test is non-specific for malondialde-
hyde(31). The mid-pregnancy malondialdehyde concentrations
were clearly lower in the women studied by Patrick et al. (30)
(0·38mmol/l in white and 0·50mmol/l in black women) than
the TBARS concentrations in the European women in the
present study (0·74mmol/l). Thus antioxidative capacity
might have been exhausted earlier in our women. An associ-
ation between lipid peroxidation products and lipid-soluble
antioxidants is reflected in the negative correlations between
TBARS and a-tocopherol in the whole study population at
w30 (r 20·21; P¼0·002). Fish oil supplementation induced
both significantly higher plasma phospholipid DHA and
EPA percentages(17) at w30 and at delivery, while plasma
TBARS concentrations were only at w30 significantly
increased in the fish oil-supplemented group. This might
indicate that the antioxidant system was brought to its limits
around w30, but adapted later on or at delivery other factors
are the determinants of redox status.
Plasma concentrations of a-tocopherol and the a-tocopherol:
lipid ratio increased after w20, which reflects the additional
intake of a-tocopherol with the study supplements. While a
negative correlation between percentage of total PUFA and
vitamin E has been reported in pregnant Italian women(32), we
did not find lower a-tocopherol concentrations in the fish
oil-supplemented women. The reason seems to be the different
amounts of vitamin E intake. None of the studied Italian
women took nutritional supplements containing lipid-soluble
vitamins(32). The additional vitamin E intake with the
Nutraceuticals for a Healthier Life (NUHEAL) study supple-
ment might have provided a-tocopherol in an amount much
higher than the minimal requirement for radical scavenging.
Plasma protection against free radical injury is offered
by a wide range of antioxidants with synergistic action.
Measurement of all individual antioxidants is not possible;
thus we applied the integrative TEAC assay to estimate
plasma antioxidative capacity. We did not find significantly
lower plasma TEAC in fish oil-supplemented compared with
non-supplemented women. In both groups TEAC tended
to decrease towards the end of the intervention period.
Comparing measured TEAC concentration with antioxidants
measured in plasma, we found significant correlations to
retinol, b-carotene and total protein levels, but no correlation
to uric acid. TEAC was not affected by the progression of
pregnancy and the significant changes in uric acid concen-
tration over time were not reflected. Plasma albumin and
uric acid are the major determinants of TEAC, but correlations
to specific antioxidant concentrations are difficult to establish
and depend on the applied radical-generating substrate and
reaction time(33 – 35).
The decrease of plasma retinol concentration during
pregnancy is in agreement with the results of Bruinse et al. (36)
and Cikot et al. (37). Possible reasons for a decrease could be
the increasing plasma volume during pregnancy, a decrease in
retinol-binding proteins or increased tissue retention. The
decreased plasma retinol concentration during advanced
pregnancy might also reflect enhanced fetal utilisation(32,38).
Significant differences in plasma b-carotene concentrations
were found between fish oil-supplemented and non-
supplemented subjects. In contrast to a short-term n-3 long-
chain PUFA supplementation study(39), we found higher
values of plasma b-carotene at w30 and at the time of delivery
in fish oil-supplemented women. All groups showed the
lowest concentrations at the time of delivery, which might
be an indication for a higher level of oxidative stress towards
the end of gestation as well as the increased maternal blood
volume. Several other factors known to influence b-carotene
concentration, such as age, sex, smoking status and residence
location, could be excluded as they were not different between
the groups (P.0·05)(40). Thus, the reason for the higher
b-carotene concentrations in the fish oil-supplemented
women remains unclear.
Uric acid plasma concentration increased significantly
throughout pregnancy, irrespective of type of supplemen-
tation. A similar increase has been reported in other studies
and has been interpreted as reflecting a xanthine–xanthine
oxidase pathway stimulation(41,42). Uric acid may act as an
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antioxidant, but there is also evidence that it has pro-oxidative
effects(43 – 45). Thus, increased levels of uric acid indicate
oxidative stress, but it is unclear whether it induces oxidative
stress or reflects antioxidant activity. In pregnancy elevated
uric acid levels have been associated with increased rates
of complications such as pre-eclampsia(42). In non-smoking
pregnant women, uric acid levels of 197 (SEM 15)mmol/l
(33·1 (SEM 2·5) mg/l) in weeks 16–24 and 194 (SEM 9)
mmol/l (32·6 (SEM 1·5) mg/l) in weeks 24–34 have been
reported(46), which is similar to our findings. In contrast,
results in smoking pregnant women (202mmol/l (33·9 mg/l);
214mmol/l (35·9 mg/l))(46) tended to be higher than the
plasma uric acid in our n-3-supplemented women (w20,
179mmol/l (30 mg/l); w30, 196mmol/l (33 mg/l)). Thus, it
appears that the increase with time found in the present
study is not related to the n-3 supplementation, but rather
with falling renal clearance towards the end of pregnancy(46).
Plasma thiol groups showed a decrease in all subjects
during the intervention time. The present results confirm the
results of previews studies(47,48). The decrease in thiol
groups and in total protein levels during pregnancy may reflect
the increasing maternal plasma volume and physiological
functions of the thiol groups in fetal metabolism, but increases
of oxidative stress with pregnancy duration has also been
proposed as an explanation(47,49,50). Our data show a similar
decrease in all supplementation groups, which was on average
20 % from baseline to delivery. Thus, if an n-3 long-chain
PUFA supplementation induced oxidative stress, it was too
small to influence plasma thiol concentration.
We conclude that the recommended supply of n-3 long-
chain PUFA in pregnancy(51,52), here providing a daily
supply of 500 mg DHA and 150 g EPA, did not affect water-
soluble and lipid-soluble antioxidants. Higher TBARS
concentrations in the fish oil group were not associated with
a depletion of plasma antioxidants, and the group difference
was clearly smaller than the increase with pregnancy duration.
Independent of the inclusion of folate the applied dosage of
n-3 long-chain PUFA supplementation seems to be without
adverse effects on antioxidative defence in pregnant women.
Acknowledgements
The authors thank all participating women for their
collaboration and all colleagues in the study centres for their
support. The present study was financially supported by the
Commission of the European Communities within the 5th
Framework Programme NUHEAL, CLK1-CT-1999-00888,
within the 6th Framework Programmes EARNEST, Food-
CT-2005-007036, and EURRECA, FP6-036196-2, and
within the 7th Framework Programme NUTRIMENTHE,
FP7-212652. This paper does not necessarily reflect the
views of the Commission and in no way anticipates the
future policy in this area. B. K. is the recipient of a Freedom
to Discover Award of the Bristol Myers Squibb Foundation,
New York, NY, USA.
All authors have made substantive contributions to the
study, and endorse the data and conclusions. The authors
contributed as follows: B. K., C. C. and T. D. designed and
supervised the study. C. F., K. M., H. D., M. C. and J. A.
M.-F. participated in data collection and/or laboratory
analyses. C. F. did the statistical analysis and wrote the first
draft of the manuscript. B. K., H. D., C. C. and T. D. revised
the manuscript and contributed to the final version of the
manuscript.
All authors certify that there is no actual or potential
conflict of interest in relation to this article.
References
1. Jenkins C, Wilson R, Roberts J, et al. (2000) Antioxidants: their
role in pregnancy and miscarriage. Antioxid Redox Signal 2,
623–628.
2. Sugino N, Takiguchi S, Kashida S, et al. (2000) Superoxide
dismutase expression in the human corpus luteum during the
menstrual cycle and in early pregnancy. Mol Hum Reprod 6,
19–25.
3. Mutlu-Turkoglu U, Ademoglu E, Ibrahimoglu L, et al. (1998)
Imbalance between lipid peroxidation and antioxidant status in
preeclampsia. Gynecol Obstet Invest 46, 37–40.
4. Perkins AV (2006) Endogenous anti-oxidants in pregnancy and
preeclampsia. Aust NZ J Obstet Gynaecol 46, 77–83.
5. Kim YJ, Hong YC, Lee KH, et al. (2005) Oxidative stress in
pregnant women and birth weight reduction. Reprod Toxicol
19, 487–492.
6. Koletzko B, Agostoni C, Carlson SE, et al. (2001) Long chain
polyunsaturated fatty acids (LC-PUFA) and perinatal develop-
ment. Acta Paediatr 90, 460–464.
7. Willatts P & Forsyth JS (2000) The role of long-chain poly-
unsaturated fatty acids in infant cognitive development.
Prostaglandins Leukot Essent Fatty Acids 63, 95–100.
8. Decsi T & Koletzko B (2005) n-3 Fatty acids and pregnancy
outcomes. Curr Opin Clin Nutr Metab Care 8, 161–166.
9. Lakin V, Haggarty P, Abramovich DR, et al. (1998) Dietary
intake and tissue concentration of fatty acids in omnivore,
vegetarian and diabetic pregnancy. Prostaglandins Leukot
Essent Fatty Acids 59, 209–220.
10. Makrides M, Duley L & Olsen SF (2006) Marine oil, and other
prostaglandin precursor, supplementation for pregnancy
uncomplicated by pre-eclampsia or intrauterine growth restric-
tion The Cochrane Database of Systematic Reviews 2006,
issue 3, CD003402. http://www.mrw.interscience.wiley.com/
cochrane/clsysrev/articles/CD003402/frame.html
11. Olsen SF, Osterdal ML, Salvig JD, et al. (2007) Duration of
pregnancy in relation to fish oil supplementation and habitual
fish intake: a randomised clinical trial with fish oil. Eur J Clin
Nutr 61, 976–985.
12. Gitto E, Reiter RJ, Karbownik M, et al. (2002) Causes of
oxidative stress in the pre- and perinatal period. Biol Neonate
81, 146–157.
13. Herrera E (2002) Lipid metabolism in pregnancy and its conse-
quences in the fetus and newborn. Endocrine 19, 43–55.
14. Homocysteine Lowering Trialists’ Collaboration (2005) Dose-
dependent effects of folic acid on blood concentrations of
homocysteine: a meta-analysis of the randomized trials. Am J
Clin Nutr 82, 806–812.
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